Compare Innovative Industrial Properties Inc (IIPR) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs 10X Genomics Inc — how do they compare? Innovative Industrial Properties Inc trades at $51.83 (market cap $1.43B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 7× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 14.64% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Innovative Industrial Properties Inc for 86 Days and 10X Genomics Inc for 91 Days on average.
| IIPR | TXG | |
|---|---|---|
Market Cap | $1.43B | $10.07B |
Volume | 394,222 | 5,657,286 |
Sector | Real Estate | Health |
52-Week High | $64.67 | $97.74 |
52-Week Low | $44.58 | $11.48 |
Typical Hold Time | 86 Days | 91 Days |
Enterprise Value | $1.96B | $9.59B |
Dividend Yield | 14.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $51.92, up 1.35% with bearish technical signals but attractive valuation metrics including P/E of 11.75 and P/B of 0.83. The REIT reported mixed Q2 2026 earnings, beating expectations with $1.36 EPS versus $1.02 expected, while revenue declined to $266M in 2025. Recent news highlights a $245M mezzanine loan commitment and a $1.90 quarterly dividend, though cash flow turned negative in 2025.
The stock presents a high-yield opportunity with 13%+ dividend yield but faces tenant default risks and sector volatility. Analyst consensus is mixed with 36% buy ratings and $84.67 price target suggesting 63% upside, though technical indicators remain bearish. Regulatory catalysts and balance sheet strength provide potential upside amid cannabis REIT sector challenges.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
